Evidence map›Paper›PMID 26728737›Full record

ArticleDoklady. Biochemistry and biophysics2015

Far-red fluorescent cell line for preclinical study of HER2-targeted agents.

I V Balalaeva, E A Sokolova, A A Brilkina, S M Deyev, R V Petrov

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

I V BalalaevaLobachevsky Nizhni Novgorod State University, Nizhni Novgorod, 603600, Russia. irin-b@mail.ru.
E A SokolovaLobachevsky Nizhni Novgorod State University, Nizhni Novgorod, 603600, Russia.
A A BrilkinaLobachevsky Nizhni Novgorod State University, Nizhni Novgorod, 603600, Russia.
S M DeyevLobachevsky Nizhni Novgorod State University, Nizhni Novgorod, 603600, Russia.
R V PetrovLobachevsky Nizhni Novgorod State University, Nizhni Novgorod, 603600, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have created novel HER2-overexpressing human ovarian adenocarcinoma cell line stably transfected with far-red fluorescent protein TurboFP635. Growth characteristics, adhesion capacity and morphology of the cells do not differ from that of parental cell line. The obtained cell line (SKOV-kat) was confirmed to have high level of expression of the tumor marker HER2 comparable to that of initial cell line SKOV-3. The SKOV-kat cell line is designed for further establishment of experimental fluorescent models of HER2-overexpressing human ovarian cancer that make it possible to optimize and reduce the cost of preclinical study of agents for treatment of this disease.

Indexed as

AdenocarcinomaCell Culture TechniquesCell LineDrug Evaluation, PreclinicalErb-b2 Receptor Tyrosine KinasesFemaleHumansLuminescent ProteinsOvarian NeoplasmsRed Fluorescent ProteinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLuminescent ProteinsRed Fluorescent Protein

Identifiers

PMID26728737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.